NHS Manchester University NHS Foundation Trust

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
25331	15/WM/0331	184594	Heart Mate 3	Range Agreed	15	20	Date Agreed	30/01/2017	20	30/01/2017	20	Recruitment Finished
25332	15/EM/0309	184678	CLEARCUT VR475	Number Agreed	3	3	Date Agreed	28/02/2017	3	06/03/2017	3	Recruitment Finished
25333	16/SC/0018	191267	EMPIRE CTX4430	Number Agreed	4	4	Date Agreed	31/03/2017	4	31/03/2017	4	Recruitment Finished
25334	15/NW/0255	163780	TANGO II	Number Agreed	4	4	Date Agreed	31/12/2017	1	08/02/2017	1	Withdrawn By Sponsor
25335	15/LO/1500	187068	BI 1199.229	Number Agreed	4	4	Date Agreed	31/01/2017	6	14/03/2017	6	Recruitment Finished
25336	16/NW/0787	216022	ALBATROSS	Number Agreed	2	2	Date Agreed	15/06/2017	4	22/06/2017	4	Recruitment Finished
25337	15/NW/0747	186601	Boehringer Biosimilar	Number Agreed	6	6	Date Agreed	02/02/2017	0	02/02/2017	0	Recruitment Finished
25338	16/SC/0341	204761	EZH-203	Range Agreed	4	5	Date Agreed	31/10/2017	1	17/05/2017	1	Withdrawn By Sponsor
25339	08/H0604/170		A Multicentre, randomised, double-blind, placebo controlled efficacy and safety trial of intravenous zoledronic acid twice yearly compared to placebo in osteoporotic children treated with glucocorticoids for chronic inflammatory conditions.	Range Agreed	1	5	Date Agreed	31/12/2016	2	01/03/2017	2	Withdrawn By Sponsor
25340	15/NW/0098	138128	A Phase 2, Multicenter, Open-Label Study To Evaluate The Pharmacokinetics, Pharmacodynamics, Safety And Activity Of Azacitidine And To Compare Azacitidine To Historical Controls In Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Synd	Number Agreed	1	1	Date Agreed	31/03/2017	0	12/09/2017	0	Recruitment Finished
25341	12/LO/1771	112563	A Phase 3 randomized, Controlled, Open-label. Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With relapsed or Refractory Systemic Light Chain (AL) Amyloidosis	Number Agreed	6	6	Date Agreed	31/05/2018	2	31/01/2017	3	Recruitment Finished
25342	14/SC/0262	151493	A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg: the SAFARI stu	Number Agreed	5	5	Date Agreed	31/10/2017	7	10/02/2017	7	Recruitment Finished
25343	14/NE/1049	155280	Einstein Junior Phase II B - 30-day, open-label, active-controlled, randomized study of the safety, efficacy and the pharmacokinetic and pharmacodynamic properties of oral rivaroxaban in young children with various manifestations of venous thrombosis	Number Agreed	1	1	Date Agreed	01/05/2017	0	15/02/2017	0	Recruitment Finished
25344	14/NE/1050	155345	Einstein Junior Phase III - Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboemb	Number Agreed	3	3	Date Agreed	27/05/2018	3	25/05/2017	3	Recruitment Finished
25345	14/WS/1078	143053	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative Colitis	Number Agreed	2	2	Date Agreed	30/06/2017	0	30/06/2017	0	Recruitment Finished
25346	15/YH/0402	187262	CNS Unmet Medical Need in Mucopolysaccharidosis: A Phase 2 Safety and Pharmacokinetics Study of Ataluren (COMPASS)	Number Agreed	1	1	Date Agreed	30/11/2016	1	13/04/2017	1	Withdrawn By Sponsor
25347	15/LO/1226	163213	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Range Agreed	1	2	Date Agreed	30/04/2017	0	19/05/2017	0	Withdrawn By Sponsor
25348	15/NW/0067	166982	ASCEND-Peds (A phase 1/2, multi-center, open-label, ascending dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of recombinant human acid sphingomyelinase in pediatric patients aged <18 years	Number Agreed	2	2	Date Agreed	31/03/2016	2	12/04/2017	2	Recruitment Finished
25349	14/NW/1354	156734	A Single Arm, Openlabel, Longterm Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)	Range Agreed	2	6	Date Agreed	28/02/2017	6	01/01/2017	6	Recruitment Finished
25350	15/YH/0017	169136	An Open Label Extension of Study HGTHIT094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction with Elaprase? in Patients with Hunter Syndrome and Cognitive Impairment	Number Agreed	3	3	Date Agreed	31/12/2016	3	01/03/2017	4	Recruitment Finished
25351	14/LO/1514	150294	An Open Label Study to Assess the Safety and Efficacy of COR?003 (2S, 4R?Ketoconazole) in the Treatment of Endogenous Cushing?s Syndrome	Number Agreed	2	2	Date Agreed	30/09/2017	1	09/06/2017	1	Recruitment Finished
25352	14/SC/1340	151325	A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/day) as Treatment in Patients with Huntington's Disease Phase II Study (TV5600-CNS	Range Agreed	4	12	Date Agreed	07/04/2017	2	04/04/2017	3	Recruitment Finished

NHS Manchester University NHS Foundation Trust

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
25353	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	Range Agreed	1	5	Date Agreed	30/04/2017	5	30/04/2017	5	Recruitment Finished
25354	15/NW/0505	177219	A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NR	Number Agreed	4	4	Date Agreed	31/12/2016	6	30/01/2017	6	Recruitment Finished
25355	15/NW/0229	170151	Worldwide Randomized Antibiotic Envelope Infection Prevention Trial	Range Agreed	30	100	Date Agreed	30/06/2018	52	25/07/2017	52	Recruitment Finished
25356	15/LO/1828	188713	RAINBOW study: a randomised, controlled study evaluating the efficacy and safety of ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity	Number Agreed	2	2	Date Agreed	31/05/2017	2	27/01/2017	2	Recruitment Finished
25357	13/NE/0005	100377	A prospective, non-interventional registry providing continuing evaluation and periodic reporting of product safety, effectiveness and patient outcomes across Medtronic market released products within diabetes, cardiac rhythm disorders, urological,	Range Agreed	5	25	Date Agreed	01/09/2018	18	28/04/2017	18	Recruitment Finished
25358	16/NE/0024	195903	Analgesic efficacy of oral dexketoprofen trometamol/tramadol hydrochloride versus tramadol hydrochloride/paracetamol: a randomised, double-blind, placebo and activecontrolled, parallel group study in moderate to severe acute pain after removal of im	Range Agreed	3	13	Date Agreed	31/12/2016	2	24/01/2017	3	Recruitment Finished
25359	16/LO/0022	195532	A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients with Severe (FVIII <1%) Hemophilia A	Range Agreed	1	2	Date Agreed	31/05/2017	2	31/01/2017	2	Recruitment Finished
25360	16/LO/0083	193141	A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Adults who Require Regular Red Blood Cell Transfusions Due to Beta (B)-thalassemia, The ?BE	Range Agreed	1	2	Date Agreed	28/02/2018	0	01/01/2017	0	Withdrawn By Sponsor
25361	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	10	Date Agreed	01/06/2017	23	31/07/2017	26	Recruitment Finished
25362	16/SC/0039	188354	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitis	Range Agreed	2	5	Date Agreed	31/05/2017	1	06/09/2017	1	Recruitment Finished
25363	16/EE/0130	200989	Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart compared to NovoRapid? in Adults with Type 1 Diabetes	Number Agreed	5	5	Date Agreed	04/01/2017	5	12/01/2017	5	Recruitment Finished
25364	13/LO/1522	137260	LTS13632 (A long-term study to assess the ongoing safety and efficacy of olipudase alfa in patients with acid sphingomyelinase deficiency)	Range Agreed	1	2	Date Agreed	31/08/2017	2	30/08/2017	2	Recruitment Finished
25365	16/LO/1854	184654	A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Ar	Range Agreed	50	100	Date Agreed	30/09/2017	56	19/05/2017	56	Recruitment Finished
25366	16/LO/0794	202764	RAINBOW extension study: an extension study to evaluate the long term efficacy and safety of ranibizumab compared with laser therapy for the treatment of infants born prematurely with retinopathy of prematurity	Number Agreed	2	2	Date Agreed	12/10/2016	2	27/01/2017	2	Recruitment Finished
25367	16/NW/0617	210749	A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients with X-linked Hypophosphatemia (XLH)	Range Agreed	1	5	Date Agreed	31/03/2017	3	31/03/2017	3	Recruitment Finished
25368	16/WA/0137	202447	A randomized, multicentre, open label, phase 3 clinical trial to evalate the efficacy, safety and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in haemophilia A patients without inhibitors	Number Agreed	2	2	Date Agreed	30/11/2017	0	31/03/2017	0	Recruitment Finished
25369	16/LO/1113	209455	A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected trea	Range Agreed	1	8	Date Agreed	30/04/2017	5	21/03/2017	6	Recruitment Finished

NHS Manchester University NHS Foundation Trust

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
25370	16/NW/0262	200188	A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Tre	Range Agreed	1	5	Date Agreed	30/04/2017	3	10/03/2017	3	Recruitment Finished
25371	16/EE/0223	201450	A 24- week, multicenter, randomised, open-label, parallel-group Study comparing the efficacy and safety of Toujeo and Trsiba in Insulin-na?ve patients with Type 2 Diabetes Mellitus not adequately controlled with oral antidiabetic drug(s) + GLP-1 rece	Number Agreed	7	7	Date Agreed	30/04/2017	5	30/01/2017	5	Recruitment Finished
25372	17/YH/0083	220358	A Randomized Controlled Trial of Gentle Touch/Early Massage with a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies	Number Agreed	30	30	Date Agreed	30/09/2017	32	30/09/2017	32	Recruitment Finished
25373	16/LO/0793	203066	BI 1199.227	Number Agreed	4	4	Date Agreed	15/03/2017	13	15/03/2017	13	Recruitment Finished
25374	15/NW/0821	191169	Oricol	Number Agreed	20	20	Date Agreed	31/07/2017	30	21/09/2017	30	Recruitment Finished
25375	13/EE/0326	137999	Revacept	Range Agreed	64	80	Date Agreed	30/05/2017	19	30/05/2017	19	Recruitment Finished
26698	15/LO/0681	174407	A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients with Early Manifest Huntington?s Disease	Number Agreed	4	4	Date Agreed	30/04/2017	4	30/04/2017	4	Recruitment Finished
26699	15/WS/0061	178522	A Randomized, Doubleblind, Eventdriven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban with Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects with Heart Failure and SignificantCoronary Artery Disease Fo	Number Agreed	5	5	Date Agreed	15/10/2017	1	31/07/2017	1	Recruitment Finished
26700	15/SC/0456	174561	AN EARLY-PHASE, MULTICENTER, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOKINETICS OF ANTI-PD-L1 ANTIBODY (MPDL3280A) IN PEDIATRIC AND YOUNG ADULTPATIENTS WITH PREVIOUSLY TREATED SOLID TUMORS	Range Agreed	1	3	Date Agreed	30/09/2017	0	29/09/2017	0	Withdrawn By Sponsor
26701	16/ES/0001	193859	A Phase 3, randomized, double-blind, placebo-controlled, multicentre study to investigate the efficacy and safety of Mongersen (GED-0301) for the treatment of subjects with active Crohn's Disease	Number Agreed	3	3	Date Agreed	31/03/2017	2	20/10/2017	2	Withdrawn By Sponsor
26702	16/WS/0005	193858	A PHASE 3, LONG-TERM ACTIVE TREATMENT EXTENSION STUDY OF MONGERSEN (GED-0301) IN SUBJECTS WITH CROHN?S DISEASE	Range Agreed	1	3	Date Agreed	30/11/2017	1	20/10/2017	1	Withdrawn By Sponsor
26703	17/LO/0212	221502	An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumabgiven as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)	Range Agreed	1	3	Date Agreed	31/07/2017	2	13/06/2017	2	Recruitment Finished
26704	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Range Agreed	1	6	Date Agreed	31/12/2017	6	27/11/2017	6	Recruitment Finished
26705	16/SC/0542	208245	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITYOF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULARDEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY	Range Agreed	1	4	Date Agreed	31/03/2018	2	20/11/2017	2	Recruitment Finished
26718	17/SC/0236	226436	PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY	Number Agreed	1	1	Date Agreed	31/12/2017	1	22/08/2017	1	Recruitment Finished
26719	16/ES/0001	193859	Revolve (Celgene GED-0301-CD-002)	Number Agreed	3	3	Date Agreed	29/11/2017	0	19/10/2017	0	Withdrawn By Sponsor
26720	17/NW/0019	212375	A3921192 SOAR ? A Study of a Once-A-day investigational drug for RA	Number Agreed	2	2	Date Agreed	21/03/2019	0	31/10/2017	0	Withdrawn By Sponsor